Pediatric Appropriate Prolonged-Release Melatonin Minitablet for Insomnia in Children and Adolescents with Autism Spectrum Disorder

Despite high rates of comorbid insomnia among children and adolescents with Autism Spectrum Disorder (ASD), and its negative impact on child development, health and quality of life, there is limited awareness among clinicians of screening for, and treatment of, insomnia in this population. Prolonged-Release Melatonin (PedPRM, available commercially as Slenyto®) is the first authorized drug for the management of insomnia in children and adolescents with ASD or Smith Magenis Syndrome (SMS) but there is little evidence on how this new medicinal product performs in real life treatment